What Is Breakthrough Pain
WHY CHOOSE DAXOCOX^®
HOW DAXOCOX^® WORKS
Dosing and Administration
DAXOCOX^® SUPPORT RESOURCES
FAQS

DAXOCOX^® 15MG X 4

8.25

Post navigation

WANT TO KNOW MORE?

Privacy Policy
Cookie policy
Terms of use

REFERENCES: 1. Daxocox^® Summary of Product Characteristics (SPC), 2021 2.Internal report: DA/197/C, pending publication 3. Internal report: DA/184/C, pending publication 4. Homedes J, et al. Long-term safety evaluation of Daxocox^® tablets (enflicoxib) in dogs after weekly oral administrations for seven months. BMC Veterinary Research (2021) 17:205 https://doi.org/10.1186/s12917-021-02910-0 5. Internal report: PK_001_2018, pending publication 6. Dacocox^® Vet Insight Executive Summary (N=200), January 2021 7. Daxocox^® Pet Owner Insight Executive Summary (N=200) January 2021 8. Internal report: EV-013/09-SN.

Daxocox^® 15mg, 30mg, 45mg, 70mg and 100mg weekly tablets for dogs. Active substance: Enflicoxib. UK POM-V, 15mg Vm 32742/5001 EU/2/21/270/001-007, 30mg Vm 32742/5002 EU/2/21/270/008-014, 45mg Vm 32742/5003 EU/2/21/270/015-021, 70mg Vm 32742/5004 EU/2/21/270/022-028, 100mg Vm 32742/5005 EU/2/21/270/029-035.

Indications for use: For the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs. Further information can be found in the SPC, the datasheet or the pack leaflet.

USE MEDICINES RESPONSIBLY. Daxocox^® is a registered trademark of Animalcare Group Plc